News

The Revimmune multiple sclerosis (MS) study will enroll subjects in a one-year study comparing baseline disability to disability at month 12 with an interim data analysis. After consultation

Critical Therapeutics and Dey have entered into an agreement for the co-promotion of inhalation product Perforomist, indicated for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic

Elaprase is an enzyme replacement therapy developed by Shire Human Genetic Therapies. Genzyme is commercializing the product in Japan and other Asia Pacific countries under an agreement with

The report demonstrates that the drug, HE3235, significantly inhibited tumor growth in a preclinical model of hormone-independent prostate cancer utilizing human tumor cells. Mechanism of action data was

In this study, a 28-day treatment course of antibiotic aztreonam lysine for inhalation improved respiratory symptoms as assessed by the cystic fibrosis questionnaire-revised (CFQ-R), a patient-reported outcome tool.

As per FDA published guidance for patient reported outcome (PRO) studies, the pivotal efficacy studies of LibiGel require the use of validated methods to measure sexual events and

The recently issued patent will expire in 2023. Dyax now has a total of nine issued US patents covering DX-88 as well as other related kallikrein inhibitors and

Adlea is a long-acting, non-opiate analgesic drug candidate designed to provide pain relief for weeks to months after a single local application during the surgical procedure. The trial

The agreement is one of two clinical studies intended to form part of the application for marketing authorization. The randomized, double-blind placebo-controlled multi-center clinical trial will be conducted